
CLAIMS

1. A pharmaceutical combination product comprising

a) a compound of formula (I):



(I)

wherein X^- is a pharmaceutically acceptable anion; and

b) a corticosteroid.

2. A product according to claim 1, which does not comprise any further therapeutically active agents.

3. A product according to claim 1 or claim 2, wherein X^- is selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate.

4. A product according to any of claims 1 to 3, wherein the compound of formula (I) is umeclidinium bromide.

5. A product according to any of claims 1 to 4, wherein the corticosteroid is selected from the group consisting of fluticasone propionate, mometasone furoate, ciclesonide, budesonide and fluticasone furoate.

6. A product according to claim 5, wherein the corticosteroid is fluticasone furoate.

7. A product according to any of claims 1 to 6, wherein the compound of formula (I) and the corticosteroid are presented in a form adapted for separate administration.

8. A product according to any of Claims 1 to 6, wherein the compound of formula (I) and the corticosteroid are presented in a form adapted for sequential administration.

9. A product according to any of Claims 1 to 6, wherein the compound of formula (I) and the corticosteroid are presented in a form adapted for simultaneous administration.

10. A product according to claim 9, wherein the compound of formula (I) and the corticosteroid are in admixture with each other.

11. A product according to any of claims 1 to 10, wherein at least one of the compound of formula (I) and the corticosteroid is formulated with a pharmaceutically acceptable carrier or excipient.

12. A product according to any of claims 1 to 11 in a form suitable for administration by oral or nasal inhalation.

13. A product according to claim 12, wherein the form is suitable for administration by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, a unit-dose dry powder inhaler, a pre-metered multi-dose dry powder inhaler, a nasal inhaler or a pressurized metered dose inhaler.

14. A product according to claim 13, wherein each of the compound of formula (I) and the corticosteroid is presented in the form of a dry powder composition.

15. A product according to claim 14, wherein the compound of formula (I) and the corticosteroid are presented as separate compositions.

16. A product according to claim 14, wherein the compound of formula (I) and the corticosteroid are presented as admixed compositions.

17. A product according to claim 15 or 16, wherein at least one of said compositions of the compound of formula (I) and the corticosteroid contains a carrier.

18. A product according to claim 15 or 16, wherein both compositions of the compound of formula (I) and the corticosteroid contain a carrier.

19. A product according to claim 17 or claim 18, wherein the carrier is lactose.

20. A product according to any of claims 14 to 19, wherein at least one of said compositions contains a ternary agent.

21. A product according to claim 20, wherein the ternary agent is magnesium stearate.

22. A product according to claim 21, wherein magnesium stearate is present in an amount of about 0.6%w/w in a composition of the compound of formula (I).

23. A product according to any of claims 14 to 22, wherein said separate or admixed compositions are in unit dose form.

24. A product according to claim 23, wherein the unit dose is in a capsule, cartridge or blister pack.

25. A product according to any of claims 14 to 24, wherein the composition is administered via a dry powder inhaler.

26. A product according to claim 25, wherein said inhaler permits separate containment of the compound of formula (I) and the corticosteroid.

27. A product according to claim 25 or 26, wherein the free cation of the compound of formula (I) is present in an amount of about 1 to 1000 mcg/dose.

28. A product according to claim 25 or 26, wherein the free cation of the compound of formula (I) is present in an amount of 125mcg/dose.

29. A product according to claim 25 or 26, wherein the free cation of the compound of formula (I) is present in an amount of 62.5mcg/dose.

30. A product according to claim 25 or 26, wherein the free cation of the compound of formula (I) is present in an amount of 31.25mcg/dose.

31. A product according to claim 25 or 26, wherein the free cation of the compound of formula (I) is present in an amount of 15.625mcg/dose.

32. A product according to any of claims 25 or 31, wherein the corticosteroid is fluticasone furoate and is present in an amount of 100mcg/dose.

33. A product according to any of claims 25 or 31, wherein the corticosteroid is fluticasone furoate and is present in an amount of 200mcg/dose.

34. A dry powder inhaler containing a product as defined in any of claims 1 to 33.

35. A dry powder inhaler according to claim 34 comprising two compositions presented separately, wherein the first composition comprises

i. umeclidinium bromide, and
ii. lactose, and
iii. magnesium stearate at an amount of about 0.6%w/w based on the total weight of the first composition;

and the second composition comprises

i. fluticasone furoate, and
ii. lactose.

36. A dry powder inhaler according to claim 35, wherein each composition is in unit dose form.

37. A dry powder inhaler according to claim 36, wherein the unit dose form is a capsule, cartridge or blister.

38. A dry powder inhaler according to claim 36 or 37 wherein umeclidinium bromide is present in an amount to deliver 125mcg/dose of the free cation.

39. A dry powder inhaler according to claim 36 or 37 wherein umeclidinium bromide is present in an amount to deliver 62.5mcg/dose of the free cation.

40. A dry powder inhaler according to claim 36 or 37, wherein umeclidinium bromide is present in an amount to deliver 31.25mcg/dose of the free cation.

41. A dry powder inhaler according to claim 36 or 37, wherein umeclidinium bromide is present in an amount to deliver 15.625mcg/dose of the free cation.

42. A dry powder inhaler according to any of claims 36 to 41 wherein fluticasone furoate is present in an amount of 100mcg/dose.

43. A dry powder inhaler according to any of claims 36 to 41 wherein fluticasone furoate is present in an amount of 200mcg/dose.

44. A product according to claim 13, wherein each of the compound of formula (I) and the corticosteroid is presented in the form of a spray composition for inhalation.

45. A product according to claim 44, wherein the compound of formula (I) and the corticosteroid are presented as separate or admixed compositions.

46. A product according to claim 44 or 45, wherein the spray composition is an aqueous solution or suspension.

47. A product according to claim 44 or 45, wherein the spray composition is an aerosol composition.

48. A product according to claim 47, wherein the aerosol composition comprises a fluorocarbon or hydrogen-containing chlorofluorocarbon as propellant.

49. A product according to claim 48, wherein the propellant is a hydrofluoroalkane.

50. A product according to claim 49, wherein the propellant is 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or a mixture thereof.

51. A product according to any of claims 47 to 50, further comprising a co-solvent.

52. A product according to any of claims 47 to 51, further comprising a surface-active agent.

53. A pressurised metered dose inhaler containing a product as defined in any of claims 1 to 13 and 47 to 52.

54. A product as defined in any of claims 1 to 53 for use in therapy.

55. A product as defined in any of claims 1 to 53 for use in the treatment of inflammatory or respiratory tract diseases.

56. A product for use according to claim 55, wherein the inflammatory or respiratory tract disease is asthma or COPD.

57. A product for use according to claim 56, wherein the product is administered once daily.

58. A method for the treatment of an inflammatory or respiratory tract disease, comprising administering to a patient in need thereof, a product as defined in any of claims 1 to 53.


59. A method of treatment according to claim 58, wherein the disease is asthma or COPD.

60. A method of treatment according to claim 59, wherein administration to a patient in need thereof is once-daily.

CLAIMS

1. A pharmaceutical combination product presented in the form of a dry powder composition for administration via a dry powder inhaler comprising

a) a compound of formula (I):



(I)

wherein X^- is a pharmaceutically acceptable anion selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate; and

b) fluticasone furoate present in an amount of 100mcg/dose;

and further wherein the product does not comprise any further therapeutically active agents.

2. A product according to claim 1, wherein the compound of formula (I) is umeclidinium bromide.

3. A product according to claim 1 or 2, wherein the compound of formula (I) and the corticosteroid are presented as separate compositions.

4. A product according to claim 3, wherein both compositions of the compound of formula (I) and the corticosteroid contain a carrier, wherein the carrier is lactose.

5. A product according to claim 3 or 4, wherein at least one of said compositions contains a ternary agent, wherein the ternary agent is magnesium stearate.

6. A product according to claim 5, wherein magnesium stearate is present in an amount of about 0.6%w/w in a composition of the compound of formula (I).

7. A product according to any of claims 1 to 6, wherein said separate compositions are in unit dose form, wherein the unit dose is in a capsule, cartridge or blister pack.

8. A product according to claim 7, wherein the free cation of the compound of formula (I) is present in an amount of 125mcg/dose, 62.5mcg/dose, 31.25mcg/dose or 15.625mcg/dose.

9. A dry powder inhaler according to claim 1 comprising two compositions presented separately in unit dose form, wherein the first composition comprises

i. umeclidinium bromide, and
ii. lactose, and
iii. magnesium stearate at an amount of about 0.6%w/w based on the total weight of the first composition;

and the second composition comprises

i. fluticasone furoate present in an amount of 100mcg/dose, and
ii. lactose.

10. A dry powder inhaler according to claim 9, wherein the unit dose form is a capsule, cartridge or blister.

11. A dry powder inhaler according to claim 9 or 10 wherein umeclidinium bromide is present in an amount of 125mcg/dose, 62.5mcg/dose, 31.25mcg/dose or 15.625mcg/dose of the free cation.

12. A product as defined in any of claims 1 to 11 for use in therapy.

13. A product as defined in any of claims 1 to 11 for use in the treatment of inflammatory or respiratory tract diseases.

14. A product for use according to claim 13, wherein the inflammatory or respiratory tract disease is asthma or COPD.

15. A product for use according to claim 14, wherein the product is administered once daily.

16. Use of a product as defined in any of claims 1 to 11 in the manufacture of a medicament for the treatment of inflammatory or respiratory tract diseases.

17. Use of a product according to claim 16, wherein the inflammatory or respiratory tract disease is asthma or COPD.

18. Use of a product according to claim 17, wherein the product is to be administered once daily.